Texas backtracks: the state tightens its THC policy six years after the hemp boom

What began in 2019 as an opening for the hemp industry in Texas has just undergone one of its most drastic changes. Since July 31, the state has been enforcing new restrictions that make most hemp-derived cannabinoid products illegal, products that for years were available in specialty stores, gas stations, and CBD dispensaries.

The measure primarily affects products containing Delta-8 THC, Delta-10 THC, THCP, and other psychoactive cannabinoids derived from hemp. While industrial hemp remains legal under certain parameters and some products with Delta-9 THC below the federal limit are still permitted, the new policy eliminates much of the market that flourished after the passage of the 2019 state law.

The change doesn't stem from a new legalization or prohibition of recreational cannabis—which remains illegal in Texas—but rather from the implementation of regulations that reclassify these cannabinoids as controlled substances after a lengthy legal battle. The decision represents a major blow to a multi-billion dollar industry that employs thousands of people in the state.

State authorities argue that the proliferation of psychoactive products sold with little regulation posed a risk to public health and facilitated access for minors. Meanwhile, business owners, patients, and industry organizations maintain that the measure leaves consumers who used these products to manage anxiety, chronic pain, and insomnia without alternatives, and also creates economic uncertainty for thousands of businesses.

The Texas case reflects the complex situation facing cannabis regulation in the United States. While some states are moving toward regulated markets for adult use, others are tightening restrictions on hemp-derived cannabinoids, attempting to close legal loopholes created after the passage of the 2018 Farm Bill.

For the cannabis industry, the message is clear: commercial growth alone does not guarantee regulatory stability. The future will depend on robust legal frameworks, scientific research, and public policies capable of balancing access with health protection.